Your session is about to expire
← Back to Search
Efgartigimod PH20 SC - prefilled syringe for Bioequivalence
Study Summary
This trial compares the effects of two doses of a drug on healthy people, to see which works best.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Frequently Asked Questions
Does this investigation accept applicants over the age of 40?
"The minimum age of admission for this clinical trial is 18 and the upper threshold is 55."
Are there any eligibility criteria for individuals to become involved in this research project?
"To qualify for this trial, candidates must be within the age bracket of 18 to 55 and demonstrate bioequivalence. In total, 120 patients will be accepted."
Has the FDA sanctioned Efgartigimod PH20 SC in pre-filled syringes?
"There is limited clinical data affirming the safety and efficacy of Efgartigimod PH20 SC - prefilled syringe, so it received a ranking of 1."
What is the magnitude of individuals involved in this trial?
"Affirmative. According to information hosted on clinicaltrials.gov, this trial is still recruiting participants as of April 5th 2023 - the last time it was updated. The research requires 120 volunteers from 2 distinct medical sites and has been publicised since March 13th 2023."
Are there still available positions for individuals to participate in this investigation?
"Affirmative. The clinicaltrials.gov database reveals that this research study, which was initially uploaded on March 13th 2023, is actively recruiting individuals for participation. It requires a total of 120 participants to be enrolled from 2 different sites."
Share this study with friends
Copy Link
Messenger